Published in Int J Clin Pract on March 01, 2005
Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J (2005) 1.10
Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis (2005) 0.95
Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. Lipids Health Dis (2009) 0.87
Postprandial metabolic heterogeneity in men with primary dyslipidaemia. Arch Med Sci (2010) 0.86
Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience). Cholesterol (2012) 0.77
The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms. Open Cardiovasc Med J (2009) 0.75
Is it time to break the fast?-a paradigm shift in clinical lipidology. Ann Transl Med (2016) 0.75
The natural history of aneurysmal coronary artery disease. Heart (1997) 2.56
Cardiovascular risk assessment of South Asians in a religious setting: a feasibility study. Int J Clin Pract (2011) 2.12
Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes (1983) 1.90
The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J (2000) 1.90
Prediction of restenosis after coronary angioplasty by use of a new index: TIMI frame count/minimal luminal diameter ratio. Circulation (2000) 1.54
Documentation of slow coronary flow by the TIMI frame count in patients with coronary ectasia. Am J Cardiol (2001) 1.49
Hyperprolactinaemia in patients with heart failure: clinical and immunogenetic correlations. Eur J Clin Invest (2002) 1.49
Thrombosis of two high-flow prosthetic valves. J Thorac Cardiovasc Surg (1971) 1.48
Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur J Clin Invest (2003) 1.47
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol (2004) 1.45
Intracoronary flow velocity measurements in adjacent stenotic and normal coronary arteries during incremental intravenous dobutamine stress and intracoronary adenosine injection. Catheter Cardiovasc Interv (1999) 1.44
Pectoral cardioverter defibrillators: comparison of prepectoral and submuscular implantation techniques. Pacing Clin Electrophysiol (1999) 1.43
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol (1999) 1.43
Critique of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): flaws in CREST and its interpretation. Eur J Vasc Endovasc Surg (2013) 1.42
QT interval in cardiac amyloidosis. Clin Cardiol (1996) 1.41
Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther (2003) 1.41
Intracoronary irradiation and stent placement in a chronic total coronary occlusion: long-term clinical, angiographic, and intracoronary ultrasound follow-up. Catheter Cardiovasc Interv (2000) 1.40
Dispersion of ventricular repolarization is determined by the presence of myocardial viability in patients with old myocardial infarction. A dobutamine stress echocardiography study. Eur Heart J (2000) 1.39
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atherosclerosis (2000) 1.39
Re: Effects of prostaglandin E1 on penile erection and erectile failure. J Urol (1988) 1.38
Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis (2009) 1.31
How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf (2009) 1.31
"Subclinical" pacemaker syndrome: a randomised study of symptom free patients with ventricular demand (VVI) pacemakers upgraded to dual chamber devices. Br Heart J (1992) 1.30
Effect of ethanol on vascular prostacyclin (prostaglandin I2) synthesis, platelet aggregation, and platelet thromboxane release. Br Med J (Clin Res Ed) (1983) 1.30
The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab (2005) 1.30
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab (2011) 1.28
Cardiotoxicity of 5-fluorouracil. Lancet (1977) 1.25
Platelet function defects in chronic alcoholism. Br Med J (Clin Res Ed) (1986) 1.23
Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Am J Cardiol (1999) 1.22
Exocrine pancreatic function in diabetes mellitus. J Clin Pathol (1984) 1.22
Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism (1983) 1.22
Assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol (1984) 1.22
Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest (1988) 1.20
Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol (2013) 1.16
Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest (2005) 1.15
Pancreatic exocrine function after truncal and highly selective vagotomy. J Clin Pathol (1981) 1.15
An investigation into the effects of bacterial lipopolysaccharide on human platelets. Eur J Haematol (1989) 1.14
Mean Platelet Volume and Platelet Distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity? Platelets (2011) 1.14
Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res (1999) 1.12
Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism? Clin Sci (Lond) (1982) 1.12
The effects of fenfluramine on in vitro platelet aggregation. Br J Clin Pharmacol (1982) 1.12
Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J (2005) 1.10
A thesis for all seasons. Nature (1991) 1.09
New developments in anti-platelet therapies: potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders. Curr Drug Targets (2001) 1.07
Adrenaline and potassium. Lancet (1984) 1.06
Prevention and treatment of the metabolic syndrome. Angiology (2004) 1.06
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int (2008) 1.06
Absence of opening click in dehiscence of mitral-valve prosthesis. N Engl J Med (1969) 1.04
Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev (2008) 1.03
The effect of non-specific beta-blockade on metabolic and haemostatic variables during hypoglycaemia. Diabetes Res (1985) 1.03
Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol (1998) 1.02
Spatial QRS-T angle: association with diabetes and left ventricular performance. Eur J Clin Invest (2006) 1.02
Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens (2000) 1.02
Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo (1993) 1.01
Experimental diabetes mellitus inhibits prostacyclin synthesis by the rat penis: pathological implications. Diabetologia (1985) 1.01
Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum (2009) 1.00
Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg (2001) 1.00
Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology (1987) 1.00
Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol (1984) 1.00
Influence of heart rate increase on uncorrected pre-ejection period/left ventricular ejection time (PEP/LVET) ratio in normal individuals. Br Heart J (1976) 0.99
Increased mortality rate from coronary artery disease following operation for coarctation of the aorta at a late age. J Thorac Cardiovasc Surg (1979) 0.99
Diagnosis and management of the metabolic syndrome in obesity. Obes Rev (2005) 0.98
Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets (2000) 0.98
Warfarin administration increases uric acid concentrations in plasma. Clin Chem (1986) 0.98
Towards a doctoral thesis through published works. Biomed Pharmacother (1993) 0.97
Association of ostium secundum atrial septal defects with mitral valve prolapse. Am J Cardiol (1976) 0.97
Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets (2007) 0.97
Is accurate rate response programming necessary? Pacing Clin Electrophysiol (1990) 0.96
Plasma creatinine and creatinine clearance in nutritional osteomalacia. Lancet (1984) 0.96
Tangier disease four decades of research: a reflection of the importance of HDL. Curr Med Chem (2006) 0.96
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids (2008) 0.96
A randomized double-blind crossover comparison of four rate-responsive pacing modes. J Am Coll Cardiol (1991) 0.96
Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukot Med (1985) 0.96
Hypothermia and pancreatitis. J Clin Pathol (1983) 0.95
Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother (2008) 0.95
Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev (2011) 0.95
Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc Res (2000) 0.94
The use of citrated whole blood in thromboelastography. Anesth Analg (2000) 0.94
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation (2000) 0.94
Continuous infusion of N-acetylcysteine reduces liver warm ischaemia-reperfusion injury. Br J Surg (2004) 0.94
Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res (2010) 0.94
Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest (1985) 0.93
Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev (2008) 0.93
Detection of myocardial injury during radiofrequency catheter ablation by measuring serum cardiac troponin I levels: procedural correlates. J Am Coll Cardiol (1999) 0.93
Lipoprotein (a) and stroke. J Clin Pathol (2000) 0.92
Excitatory receptor-prostanoid synthesis coupling in smooth muscle: mediation by calcium, protein kinase C and G proteins. Prostaglandins Leukot Essent Fatty Acids (1988) 0.92
Effect of diflunisal on in vitro platelet aggregation. Lancet (1980) 0.92
Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol (2009) 0.92
A review of the metabolic effects of sibutramine. Curr Med Res Opin (2005) 0.92
Postprandial hypertriglyceridaemia in patients with Tangier disease. J Clin Pathol (2003) 0.92
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin (2005) 0.92
Thromboxane A2 analogue (U-46619) stimulates vascular PGI2 synthesis. Eur J Pharmacol (1985) 0.92
Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health (2004) 0.92
Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol (1997) 0.92
Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"? J Physiol Pharmacol (2008) 0.91